Olaparib Disappoints as Maintenance in Metastatic NSCLC
Adding olaparib to pembrolizumab maintenance did not improve outcomes in patients with metastatic squamous NSCLC in a phase 3 trial.
Adding olaparib to pembrolizumab maintenance did not improve outcomes in patients with metastatic squamous NSCLC in a phase 3 trial.
Northwestern Memorial Foundation raises funds to support the relentless pursuit of better medicine.
Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
Today, thousands of people will be diagnosed with cancer. Your gift helps improve the quality of life for cancer patients, survivors, and their loved ones.
Did you know that drinking alcohol can affect your cancer risk, lead to long-term health issues and impact your microbiome, sleep and brain function? Our…
Childhood Brain and Other Nervous System Cancer statistics
Researchers sought to develop and implement a web-based tool to enhance involvement, communication, and shared decision making among clinicians, patients with cancer, and their caregivers.
The NCI SBIR Innovation Lab podcast reaches and engages with entrepreneurs of all levels to share insights on commercialization and success stories from biotech industry…
Biennial screening mammography is recommended for those who are 40 to 74 years old rather than individualizing screening decisions in this age group.
Cancer Research | 84 | 9 | May 2024